Images

Lifestyle and biological factors drive shared pathways behind neuropsychiatric and physical disease comorbidity.

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

Visual explanation of how MAO-B inhibitors help preserve dopamine levels in the synapse in Parkinson’s disease treatment

Comparison of natural dopamine and dopamine agonists and their mechanisms of action at the synapse in Parkinson’s disease therapy.